Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNRm-1
- Development stage
- Preclinical
- Lead developer
- TenNor Therapeutics
- Modality
- Small Molecules
01
Overview
TNRm-1 is a broad-spectrum bifunctional small molecule candidate developed by TenNor Therapeutics for the treatment of metabolic diseases. It is designed using TenNor's proprietary Multi-Targeting Drug Conjugate (MTDC) technology platform, which focuses on creating single small molecules with dual or multiple biological activities. This approach aims to achieve synergistic therapeutic effects and improved safety profiles compared to traditional therapies. While the program is part of TenNor's strategic expansion into metabolic health, specific molecular targets and the precise mechanism of action for TNRm-1 have not yet been publicly disclosed. The candidate is currently in the internal development stage.
Beyond the preview
Go deeper on TNRm-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNRm-1.